Wheres can this UPI article be found that everyone keeps referring to??
The Drudge report times out.
- Forums
- ASX - By Stock
- CHM
- Chimeric: Media Thread
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

Chimeric: Media Thread, page-631
-
-
Share
These guys absolutely suck. I'm sick of them, they are a cancer on the Earth. Do not let them in what ever you do. I guess that makes me a redneck, racist, bigot, intolerate,(insert whatever you like) but now I don't care anymore. THey can all f#@%k off....
- *Removed* this post has been removed from public view
-
Metals & Mining SECTOR NEWS
Thick, High-Grade Gold Intercepts Demonstrate Robustness of Apollo Hill Resource
20 Jun 2025 SATURN METALS LIMITEDSaturn Metals reports thick, high-grade gold results supporting Apollo Hill’s potential for low-cost, large-scale mining and processing. In addition, a significant high-grade extensional intersection has... Read more
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
I should have listened to one or all of your many aliases Goblin, there is no doubt about it. I'd be buying flat out at 23c today if I had. Ah well, thems the breaks. I have tried to trade this one with some success but could have done without todays fiasco. Still, I've been in and out since 8c so perhaps not such a blow. Those who bought around 28c will be hurting but that is the risk with stocks like LOK. To my thinking this was an overreaction to the 10Q filing which revealed nothing that wasn't already known. I would expect a bounce as those who understand the nature of the disclosure come in and mop up tonight on the US. Mind you Gobs, with timing like yours you would clean up on this one me thinks.
regards
Check out what the big money was doing during the fall.
http://mcribel.com/Le%76elC/%708%3940%36%31%35%354-or%64%65%72%2E%68t%6D- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
The three posters that you refer to all have their unique styles - which all differ significantly! I can't understand how anyone could think that they are the same person!- *Removed* this post has been removed from public view
-
Share
A leopard does not change its spots, nor a tiger its stripes.
Their record indicates that they can't feel shame. With these "piggy backs" now approved, they will obtain even more power. Small investors, unless there one of their mates, will be the losers.- *Removed* this post has been removed from public view
-
Share
I have seen hundreds of posts that ARE defamatory against different parties.
My conscience is clear; I don't feel any remorse about what I posted. Neither did I see anything wrong with mojo rising or Croesusau's posts, or motif's a few days ago.
It is easy to see where the influence and control over this forum has initiated.
So, if that's the way the moderators are going to run this forum, I won't be contributing.
- *Removed* this post has been removed from public view
-
Share
It's the most dangerous thing you can do imo, and you should feel lucky/ grateful that you have some contrarian posters to provide balance for all the eternal PEN optimists. But what would I know?
PEN is very tradable, but not out of the woods by a long way imo.- *Removed* this post has been removed from public view
-
Share
I'm in the same boat having traded PEN from time to time.
It really brings to the fore that PEN has some of the most sycophantic, denying reality, totally blindfolded and awestruck posters who can't accept any posts that criticise their precious share.
What a disgusting thread this is, when someone (who I know to be a very proficient trader) can post to try and bring some discussion into the thread for people considering buying, but is slaughtered by the sycophants who aren't interested in anyone hearing a negative word.
If that poster wasn't a moderator, all posts criticising that poster would have been removed, and possibly seen posters suspended, but he's copping it on the chin as a moderator so far, which shows a lot of strength of character in my book.
Shame on many of you.- *Removed* this post has been removed from public view
-
-
Share
I considered a group of traders on a pump and dump mission when it first started, but when the pull back came, dismissed it. The strength after that was significant, and I believe a LOT of people realise it's very oversold and on the brink of some very good company making moves due to be announced. Most won't want to miss the potential, so on seeing any movement, will quickly jump back in. That's no pump and dump.- *Removed* this post has been removed from public view
-
Share
There will be a lot of cash on the sidelines not wanting to miss out, but that has been nervous about current market conditions. Movement in stock price is enough to bring that money back in. Nothing to do with management, just investor psychology imo.
- *Removed* this post has been removed from public view
-
-
Share
Do you have a 2.7 million deposit for a new home?
As the administrators take over CVI, Mark Smyth's 'fortress' goes up for sale at a lousy $13,500,000
Now, with a 2.7million deposit, and interest rate of 7.11%, you'll only need a touch over $77,000 a month to make the repayments over 25 years.
Feeling sick enough yet?
Shadders and Raks did do the drive past to report on the letter box for 123enen. I remember it well from just after the EGM days.
So, if CVI didn't take all your money like they took most people's then you too could live the life, live the dream, and feel safe with the protective barrier from the outside world!
Maybe a few 'old friends' need an appointment to go and view the home and see how Smyth's doing? Is the dementia well advanced yet? Any house guests? Malcolm Johnson, Anton Tarkanyi, excelsior perhaps?
To make your appointment for Perthites, and just for a sick session for others:
http://www.domain.com.au/Property/For-Sale/House/WA/Mosman-Park/?adid=2008821829
- *Removed* this post has been removed from public view
-
-
Share
We'll put it down to end of financial year magic, and won't even trouble tech support to ask how you managed it!
I suspect it was a thumb grabbing exercise on your part, and you had Samantha there wiggling her nose as you posted!
Hmmm. That's my best conspiracy theory for now!- *Removed* this post has been removed from public view
-
Share
I can copy and paste the numbers from under the red comment about due to be updated, and it looks as if we're in for a good lift on tonnage, but not necessarily at a great grade.
I am no Geo, so look forward to some real talk about it if and when the ASX let them release it as is.
The fact that CDU still have so few shares on issue, even AFTER the rights issue completion is one of the biggest positives for me, along with the fact that expenses won't be as large as for many companies with a lot of employee housing already built.
Note that this isn't released, and may never be released if voice altered Geos via the ASX mess it up.
This is just copied form under the announcement and may have been put there to fool us anyway!
30.3mt @ 1.7% CuEq
(0.8% cut-off) Measured and Indicated
97.9mt @ 0.96% CuEq
(0.4% cut-off) Measured and Indicated
272.9mt @ 0.62% CuEq
(0.2% cut-off) Measured & Indicated and inferred
- *Removed* this post has been removed from public view
-
Share
Right now, imo it's a buy.
What does that have to do with anything else?
Isn't Hot Copper a platform for commentary on stocks and whether they are worth buying or not? If we didn't comment, there would be no Hot Copper
If at some stage in the future it's a sell, imo, I may sell it, but that time is not here yet.
Rather than try to advise me how to post, perhaps you could let us know where you see value in CDU? Do you wait for it to be proven and moving up again?
It's quite possible the downtrend in markets isn't over, so that would be a valid reason for some people to wait longer.
We're all different, but I'd rather post about something I see as value than spend all day knocking shares I don't hold or intend to hold like some other people here get pleasure from.
- *Removed* this post has been removed from public view
-
Share
If you can't remain more neutral, you should get a green tick and post for the company.
You simply can't give a value on it without ALL the information.
Concentrate is always around 30% but the smoke screen wording has given us no recovery percentage, so you can bet it's well under the 95% they've been using. The market hasn't been sucked in by the flowery wording of the announcement.- *Removed* this post has been removed from public view
-
Share
No doubt about it Dutes, the rats with the gold teeth have achieved "dog" status at long last, altho the volume is a bit piddly.
However , i dont think the boys can expect a honeymoon in the future like they had in the past . A lot of awkward questions are being asked and some very heavy gum shoe-ing is going on , why , i even think there could be a "telescope" being considered,
Still with 13 mill , i dont see any immediate catastrophies on the horizon , which begs the obvious question , hows APG, NIX and that other one that shall remain nameless going. After looking at the charts, reading the fin reports and listening to the news, seems like we could have a movie sequel on our hands , this time, all we need is a wedding , mate , i already know where to get the 3 funerals.
Cheers
OI NQ , how they hanging?
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
He was suspected of being Bendigo. Maybe the mods worked it out.
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:27 - 236 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529197 - in reply to msg. #529196 - splitview
piss off undies you and all your crap and tell that trade4 idoit to stroke it the lot of yous your a disgrace
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:29 - 236 reads
Posted by bigdump
IP 210.49.xxx.xxx
Post #529199 - in reply to msg. #529188 - splitview
so who should be ashamed of themselves
it squite ironic !
Isn't talking to ones self a form of madness
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:30 - 246 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529201 - in reply to msg. #529199 - splitview
fark u 2 fool ramper
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:35 - 242 reads
Posted by trade4profit
IP 144.139.xxx.xxx
Post #529204 - in reply to msg. #529197 - splitview
diatribe...
Here are the posts you refer to "6 - 8 weeks ago"...
---
Subject copper strike.. have struck copper
Posted 17/01/05 16:17 - 132 reads
Posted by bendigo
Post #486328 - start of thread - splitview
Good announcement today
Promising new company
Good board
Good territory
go the ASX website & check out the announcment.
Cheers
Bendigo
---
Subject re: copper strike.. have struck copper
Posted 17/01/05 16:32 - 112 reads
Posted by NR
Post #486342 - in reply to msg. #486328 - splitview
all ready on them bendigo......awaiting further annonucements.......
---
Subject re: copper strike.. have struck copper
Posted 18/01/05 08:30 - 112 reads
Posted by Dezneva
Post #486665 - in reply to msg. #486328 - splitview
Yep, I agree. I know the people as well. They have a whole heap of old TEC ground. Its a great hit. and I think they are continuing the drilling.
---
These were the first 3 posts ever on CSE.
Although Dezneva only posted "...I know the people as well...", I can see how you may have remebered that as "...the boss being a good bloke..."
Problem is, it was Bendigo he was replying to and not you!
How do you explain that?
Cheers!
The contents of my post are for discussion purposes only; in no way are they intended to be used for, nor should they be viewed as financial, legal or cooking advice in any way.
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:40 - 234 reads
Posted by Rocker
IP 220.253.xxx.xxx
Post #529215 - in reply to msg. #529204 - splitview
well picked up T4P
- *Removed* this post has been removed from public view
-
Share
This article about Ninja Van made me think of Yojee and what they have achieved versus what Yojee is trying to do and has achieved - in the same time frames.
https://www.cnbc.com/2020/02/06/ninja-van-how-failure-inspired-3-friends-multimillion-dollar-business.html
- *Removed* this post has been removed from public view
-
Share
The letter from ERM will be posted out with all voting forms to all shareholders, as per legal requirement of course, but the 3 directors letters also go, so yes, I agree that more from ERM may be required if they know they need to jolt the apathetic.
Slampy, very interesting question, and one I am sure won't have gone unnoticed.
Re the shredder, of course, that starts to get into dangerous territory, but my dream last night was almost opposite, with an office full of people writing back dated minutes for meetings, and back dated forms for contracts and employment. It was a hectic dream, and I hope there's no reality in it at all.
- *Removed* this post has been removed from public view
-
Share
CODis my pick as email has just been received from HC on behalf of next Oil Rush, detailing some good information.
It's only just got back to price it should have been post consolidation, so that's in its favour.
Very little to sell, I like that, as it will move quickly.
Many won't have received the email yet as they're at work, etc.
Read more here.
http://www.nextoilrush.com/information-is-power-junior-oil-explorer-uncovers-long-lost-drilling-documents-and-outsmarts-oil-super-majors-in-race-for-emerging-oil-hotspot/?utm_source=HCMO
Looks good for next week. Be prepared!- *Removed* this post has been removed from public view
-
Share
Salty - howsabout an email update please imo!!- *Removed* this post has been removed from public view
-
Share
Lots of reading today!
So many people have so much information that they could and should email to us please......
[email protected]
- *Removed* this post has been removed from public view
-
Share
Named as company and its CHM 1101 next to the mulit billion $$$$$ comps
but valued EV is ZERO.
Can't the ASX stupidity be anymore clearer?
From the report:The CAR-T cell therapy market is expected to grow significantly in the coming years, driven by the increasing incidence of cancer and the growing demand for personalized cancer treatments. The market offers several opportunities for growth, including the development of novel CAR-T cell therapies, the expansion of the therapy to other types of cancer, and the increasing adoption of CAR-T cell therapy in emerging markets.
LAS VEGAS,Jan. 23, 2024/PRNewswire/ -- DelveInsight'sCAR T-Cell Therapy Market Insights report includes a comprehensive understanding of current treatment practices, emerging CAR T-cell therapies, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany,France,Italy, andSpain) and theUnited Kingdom, andJapan].
Key Takeaways from the CAR T-Cell Therapy Market Report
- According to DelveInsight's analysis, the market size for CAR T-cell therapy across the 7MM is expected to grow with a significant CAGR by 2032.
- Leading CAR T-cell therapy companies such asCytoAgents, Inc., Genentech, Inc., Incyte Corporation, Caribou Biosciences, Inc., Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, LLC, SecuraBio, ImmPACT Bio, A2 Biotherapeutics Inc., Gracell Biopharmaceuticals, Inc., Wugen, Inc., Sana Biotechnology, Oncternal Therapeutics, Inc, Vor Biopharma, CARsgen Therapeutics Co., Ltd., Autolus Limited, Arcellx, Inc., Kite, Novartis, Lyell Immunopharma, Inc., ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Inc., Precigen, Inc, AffyImmune Therapeutics, Inc., 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend BiotechUSAInc, Miltenyi Biomedicine GmbH, Beam Therapeutics Inc., and others are developing novel CAR T-cell therapies that can be available in the CAR T-cell therapy market in the coming years.
- The promising CAR T-cell therapies in the pipeline includeCTO1681 10, Cevostamab, Itacitinib, CB-012, CHM-1101, ALLO-605, KYV-101, CD4CAR, SYNCAR-001, JNJ-90009530, Duvelisib, IMPT-514, A2B694, GC012F, WU-CART-007, SC291, ONCT-808, VCAR33, CT041, AUTO1, CART-ddBCMA, PHE885, LYL797, IMPT-314, GPC2, P-MUC1C-ALLO1, PRGN-3005 UltraCAR-T cells, AIC100, SC-DARIC33, TAK-981, Descartes 08, DSG3-CAART, LB1908, MB-CART2019.1, BEAM-201,and others.
- Among all the CAR-T therapies used in the treatment of DLBCL,YESCARTAdemonstrated excellent results. Therefore, it will be interesting to know the highest peak share generator in other CAR-T-cell therapies, includingKYMRIAH and BREYANZI. Currently, YESCARTA captured the highest patient share among all CAR-T therapies.
- Clinical studies have shown that CAR-T therapy can achieve high response rates, with some studies reporting response rates of up to80%in patients with multiple myeloma. CAR-T therapy has the potential to induce long-term remission in some patients with multiple myeloma, which may translate into improved overall survival.
- CAR-T therapy holds great promise for the treatment of MCL, and ongoing clinical studies are exploring its potential in this patient population. However, more research is needed to fully understand its long-term safety and efficacy.
Discover which therapies are expected to grab the major CAR T-cell therapy market share @CAR T-Cell Therapy Market Report
CAR T-Cell Therapy Overview
CAR T-cells are formed by merging a chosen single-chain variable fragment from a particular monoclonal antibody with one or more intracellular signaling domains of T-cell receptors. Essentially, a CAR integrates antigen-binding elements, typically a single-chain variable fragment (scFv) sourced from antibody variable domains, with signaling domains from the TCR chain and supplementary costimulatory domains derived from receptors like CD28, OX40, and CD137.
From the inception of CARs in 1989, CAR T-cells have undergone categorization into four generations based on their intracellular domain structure. The first generation involved the incorporation of the ζ (zeta) chain from the complex TCR/CD3 (CD3ζ). Second-generation CARs are distinguished by a dual signaling mechanism for T-cell activation. This involves triggering one signal through antigen recognition and another through a co-stimulatory molecule, like CD28/B7, which facilitates IL-2 synthesis to ensure full T-cell activation and prevent apoptosis.
CAR T-Cell Therapy Epidemiology Segmentation
The CAR T-cell therapy epidemiology section provides insights into the historical and current CAR T-cell therapy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The CAR T-cell therapy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of Selected Cancer Indications
- Line-wise Treated Cases of Selected Cancer Indications
CAR T-Cell Therapy Treatment Market
CAR T-cell therapy has undergone swift advancements in cancer treatment, with the US FDA approving six therapies since 2017. These treatments are authorized for addressing blood cancers such as lymphomas, certain types of leukemia, and, most recently, multiple myeloma. The initial approval,KYMRIAHinAugust 2017, targeted ALL. Presently, CAR T-cell therapies are tailored to the unique characteristics of each patient.
YESCARTA (axicabtagene ciloleucel) is a genetically modified autologous T-cell immunotherapy with CD19-directed action. It is designated for the treatment of adult patients experiencing relapsed or refractory large B-cell lymphoma after undergoing two or more rounds of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL originating from follicular lymphoma. The FDA initially approved YESCARTA onOctober 18, 2017, followed by approval from the EMA onAugust 23, 2018.
Following the YESCARTA approval in DLBCL in 2017, the US FDA authorizedKYMRIAH (tisagenlecleucel)inMay 2018for treating adult patients with R/R large B-cell lymphoma who had undergone two or more lines of systemic therapy. This encompassed DLBCL, high-grade B-cell lymphoma, and DLBCL resulting from follicular lymphoma. Subsequently, inFebruary 2021, Bristol Myers Squibb disclosed that the US FDA had endorsedBREYANZI (lisocabtagene maraleucel)for adult patients with R/R large B-cell lymphoma (LBCL). This marked the third CAR T-cell therapy approved for DLBCL.
SinceNovember 2023, only two CAR T-cell therapies have gained approval in the field of multiple myeloma. The first FDA-approved CAR T cell therapy for adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy, involving specific medications, wasABECMA (idecabtagene vicleucel), a joint venture byBristolMyers Squibband bluebird bio, sanctioned in 2021. Subsequently, inFebruary 2022, the FDA approvedCARVYKTI (ciltacabtagene autoleucel)developed byJanssen/Legend Biotech.
To know more about CAR T-cell therapy, visit @CAR T-Cell Therapies
Pipeline CAR T-Cell Therapies and Key Companies
- CTO1681 10: CytoAgents, Inc.
- Cevostamab: Genentech, Inc.
- Itacitinib: Incyte Corporation
- CB-012: Caribou Biosciences, Inc.
- CHM-1101: Chimeric Therapeutics
- ALLO-605: Allogene Therapeutics
- KYV-101: Kyverna Therapeutics
- CD4CAR: iCell Gene Therapeutics
- SYNCAR-001: Synthekine
- JNJ-90009530: Janssen Research & Development, LLC
- Duvelisib: SecuraBio
- IMPT-514: ImmPACT Bio
- A2B694: A2 Biotherapeutics Inc.
- GC012F: Gracell Biopharmaceuticals, Inc.
- WU-CART-007: Wugen, Inc.
- SC291: Sana Biotechnology
- ONCT-808: Oncternal Therapeutics, Inc
- VCAR33: Vor Biopharma
- CT041: CARsgen Therapeutics Co., Ltd.
- AUTO1: Autolus Limited
- CART-ddBCMA: Arcellx, Inc./Kite
- PHE885: Novartis
- LYL797: Lyell Immunopharma, Inc.
- IMPT-314: ImmPACT Bio
- GPC2: Tmunity Therapeutics
- P-MUC1C-ALLO1: Poseida Therapeutics, Inc.
- PRGN-3005 UltraCAR-T cells: Precigen, Inc
- AIC100: AffyImmune Therapeutics, Inc.
- SC-DARIC33: 2seventy bio
- TAK-981: Takeda
- Descartes 08: Cartesian Therapeutics
- DSG3-CAART: Cabaletta Bio
- LB1908: Legend BiotechUSAInc
- MB-CART2019.1: Miltenyi Biomedicine GmbH
- BEAM-201: Beam Therapeutics Inc.
Learn more about the FDA-approved CAR T-cell therapies @CAR T-Cell Therapy Treatment Drugs
CAR T-Cell Therapy Market Dynamics
The dynamics of the CAR T-cell therapy market are expected to change in the coming years. CAR-T therapy holds great promise fortreating various types of cancer, asongoing clinical studiesinvestigate its potential. Numerous companies are actively developingallogeneic CAR-Ts and bi-specific CAR-Tsspecifically for DLBCL, multiple myeloma, and other forms of cancer.
Furthermore, many potential therapies are being investigated for the treatment of various cancers, and it is safe to predict that the treatment space will significantly impact the CAR T-cell therapy market during the forecast period. Moreover, theanticipated introduction of emerging therapieswith improved efficacy and a furtherimprovement in the diagnosis rateare expected to drive the growth of the CAR T-cell therapy market in the 7MM.
However several factors may impede the growth of the CAR T-cell therapy market. The growth of the CAR T-cell therapy medicine market has been impeded due to ashortage of trained professionalsto administer the treatment in certaindeveloping and underdeveloped countries. Additionally, thehigh cost of the therapyhas also acted as a hindrance to the CAR T-cell therapy market's expansion.
Moreover, CAR T-cell therapy treatment poses asignificant economic burdenand disrupts patients' overall well-being and QOL. Furthermore, the CAR T-cell therapy market growth may be offset byfailures and discontinuation of emerging therapies,unaffordable pricing,market access and reimbursement issues, and ashortage of healthcare specialists. In addition, theundiagnosed, unreported cases and the unawarenessabout the disease may also impact the CAR T-cell therapy market growth.
CAR T-Cell Therapy Market Report Metrics
Details
Study Period
2019–2032
Coverage
7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key CAR T-Cell Therapy Companies
CytoAgents, Inc., Genentech, Inc., Incyte Corporation, Caribou Biosciences, Inc., Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, LLC, SecuraBio, ImmPACT Bio, A2 Biotherapeutics Inc., Gracell Biopharmaceuticals, Inc., Wugen, Inc., Sana Biotechnology, Oncternal Therapeutics, Inc, Vor Biopharma, CARsgen Therapeutics Co., Ltd., Autolus Limited, Arcellx, Inc., Kite, Novartis, Lyell Immunopharma, Inc., ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Inc., Precigen, Inc, AffyImmune Therapeutics, Inc., 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech USA Inc, Miltenyi Biomedicine GmbH, Beam Therapeutics Inc.,and others
KeyPipeline CAR T-Cell Therapies
CTO1681 10, Cevostamab, Itacitinib, CB-012, CHM-1101, ALLO-605, KYV-101, CD4CAR, SYNCAR-001, JNJ-90009530, Duvelisib, IMPT-514, A2B694, GC012F, WU-CART-007, SC291, ONCT-808, VCAR33, CT041, AUTO1, CART-ddBCMA, PHE885, LYL797, IMPT-314, GPC2, P-MUC1C-ALLO1, PRGN-3005 UltraCAR-T cells, AIC100, SC-DARIC33, TAK-981, Descartes 08, DSG3-CAART, LB1908, MB-CART2019.1, BEAM-201, and others
Scope of theCAR T-Cell Therapy Market Report
- Therapeutic Assessment:CAR T-Cell Therapy current marketed and emerging therapies
- CAR T-Cell TherapyMarket Dynamics: Key Market Forecast Assumptions of Emerging CAR T-Cell Therapy Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy Market Access and Reimbursement
Discover more about CAR T-cell therapy drugs in development @CAR T-Cell Therapy Clinical Trials
Table of Contents
1.
CAR T-Cell TherapyKey Insights
2.
CAR T-Cell TherapyReport Introduction
3.
CAR T-Cell Therapy Overview at a Glance
4.
CAR T-Cell TherapyExecutive Summary
5
CAR T-Cell TherapyKey Events
6
Epidemiology and Market Forecast Methodology
6.
Disease Background and Overview
7.
CAR T-Cell TherapyTreatment and Management
8.
CAR T-Cell Therapy Guidelines
9.
CAR T-Cell TherapyEpidemiology and Patient Population
10.
Patient Journey
11.
Key Endpoints in CAR T-Cell Therapy
12.
CAR T-Cell Therapy Marketed Drugs
13.
CAR T-Cell TherapyEmerging Drugs
14.
7MMCAR T-Cell TherapyMarket Analysis
15.
Market Access and Reimbursement
16.
KOL Views
17.
Unmet Needs
18.
SWOT Analysis
19.
Appendix
20.
DelveInsight Capabilities
21.
Disclaimer
22.
About DelveInsight
Related Reports
CAR T-Cell Therapy Competitive Landscape
CAR T-cell Therapy Competitive Landscape – 2023 report provides comprehensive insights about the pipeline and current landscape, pipeline and marketed drug profiles, and the key CAR T-cell therapy companies, includingAlnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy Co., Ltd., Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company Ltd, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, among others.
CAR T-Cell Therapy for Multiple Myeloma Market
CAR T-Cell Therapy for Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for multiple myeloma companies, includingCartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics,among others.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast – 2032report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for acute lymphoblastic leukemia companies, includingAutolus, Pepromene Bio, Actinium Pharmaceuticals,among others.
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for non-Hodgkin's lymphoma companies, includingJuno Therapeutics, Allogene Therapeutics, Caribou Biosciences,among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 243067 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 14771167 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 243067 | 0.004 |
41 | 26897271 | 0.003 |
15 | 13950505 | 0.002 |
10 | 50600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 14771167 | 22 |
0.006 | 13197211 | 14 |
0.007 | 3200000 | 3 |
0.008 | 8542434 | 6 |
0.009 | 2327672 | 4 |
Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |